This paper has been peer reviewed.
1440-1681/asset/cep_bg_left.gif?v=1&s=94610148f173fa72ed6722456a9495d0f5469a5e)
1440-1681/asset/cep_centre.gif?v=1&s=d15dbde7e4b05a09ab4a0fa14e80b8d68a1ffb99)
You have free access to this content
ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Article first published online: 12 MAY 2006
DOI: 10.1111/j.1440-1681.2006.04403.x
Issue
Clinical and Experimental Pharmacology and Physiology
Volume 33, Issue 5-6, pages 533–540, May/June 2006
Additional Information
How to Cite
Chan, J. H., Lim, S. and Wong, W. F. (2006), ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION. Clinical and Experimental Pharmacology and Physiology, 33: 533–540. doi: 10.1111/j.1440-1681.2006.04403.x
Publication History
- Issue published online: 12 MAY 2006
- Article first published online: 12 MAY 2006
- Received 18 October; revision 1 February 2006; accepted 5 February 2006.
REFERENCES
- 1. Progress in antisense technology. Annu. Rev. Med. 2004; 55: 61–95.
- 2, , , , , . Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J. Biol. Chem. 2004; 279: 17 181–9.
- 3. Antisense technologies. Improvement through novel chemical modification. Eur. J. Biochem. 2003; 270: 1628–44.
- 4, . Selecting optimal antisense reagents. Adv. Drug Deliv. Rev. 2000; 44: 23–34.
- 5, , , , , . Antisense DNAs as multisite genomic modulators identified by DNA microarray. Proc. Natl Acad. Sci. USA 2001; 98: 9819–23.
- 6, , et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 1998; 16: 59–63.
- 7, , . Effects of RNA secondary structure on cellular antisense activity. Nucleic Acids Res. 2000; 28: 1340–7.
- 8, , . Secondary structure prediction of interacting RNA molecules. J. Mol. Biol. 2005; 345: 987–1001.
- 9. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003; 31: 3406–15.
- 10, , . Sfold web server for statistical folding and rational design of nucleic acid. Nucleic Acids Res. 2004; 32: W135–W141.
- 11, . Statistical prediction of single-stranded regions in RNA secondary structure and application to predict effective antisense target sites and beyond. Nucleic Acids Res. 2001; 29: 1034–46.
- 12, , . Concepts to automate the theoretical design of effective antisense oligonucleotides. Bioinformatics 2001; 17: 1058–61.
- 13, . TargetFinder: A software for antisense oligonucleotide target site selection based on MAST and secondary structures of target mRNA. Bioinformatics 2005; 21: 1401–2.
- 14, , , . Optimization of antisense drug design against conservative local motif in stimulant secondary structures of HER-2 mRNA and QSAR analysis. Acta Pharmacol. Sin. 2003; 24: 897–902.
- 15, , et al. Identification of sequence motifs in oligonucleotides whose presence is correlated with antisense activity. Nucleic Acids Res. 2000; 28: 2862–5.
- 16, , et al. Potent antisense oligonucleotides to the human multidrug resistance-1mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res. 1996; 24: 1901–7.
- 17, , , , . Predicting oligonucleotide affinity to nucleic acid targets. RNA 1999; 5: 1458–69.
- 18, , et al. Thermodynamic criteria for high hit rate antisense oligonucleotide design. Nucleic Acids Res. 2003; 31: 4989–94.
- 19, . Prediction of VEGF mRNA antisense oligodeoxynucleotides by RNA structure software and their effects on HL60 and K562 cells. Cell Biol. Int. 2005; 29: 737–41.
- 20, . Computational antisense oligo prediction with a neural network model. Bioinformatics 2002; 18: 1567–75.
- 21. Phosphorothioate oligonucleotides: What is their origin and what is unique about them? Antisense Nucleic Acids Drug Dev. 2000; 10: 117–21.
- 22. Progress in antisense technology: The end of the beginning. Methods Enzymol. 2000; 313: 3–45.
- 23The Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am. J. Ophthalmol. 2002; 133: 467–74.
- 24, , et al. Second-generation antisense oligonucleotides: Structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem. Soc. Trans. 1996; 24: 630–7.
- 25, , , , , . Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J. Biol. Chem. 1999; 274: 1715–22.
- 26, , et al. Tissue disposition of 2′-O-(2-mehtoxy) ethyl modified antisense oligonucleotides in monkeys. J. Pharm. Sci. 2004; 93: 48–59.
- 27, . Antisense therapy for cancer. Nat. Rev. Cancer 2005; 5: 468–79.
- 28, , , . Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254: 1497–500.
- 29. PNA technology. Mol. Biotechnol. 2004; 26: 233–48.
- 30, . Cellular delivery of peptide nucleic acid (PNA). Adv. Drug Deliv. Rev. 2003; 55: 267–80.
- 31, . The MYCN oncogene as a specific and selective drug target for peripheral and central nervous system tumors. Curr. Cancer Drug Targets 2005; 5: 273–83.
- 32, . The peptide nucleic acid (PNAs): A new generation of probles for genetic and cytogenetic analyses. Ann. Genet. 2004; 47: 349–58.
- 33, . LNA (locked nucleic acid): High-affinity targeting of complementary RNA and DNA. Biochemistry 2004; 43: 13 233–41.
- 34, , , . Design of antisense oligonucleotides stabilized by locked nucleic acid. Nucleic Acids Res. 2002; 30: 1911–18.
- 35, . LNA: A versatile tool for therapeutics and genomics. Trends Biotechnol. 2003; 21: 74–81.
- 36, , , , , . A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis. Oligonucleotides 2004; 14: 199–209.
- 37, , et al. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochemistry 2005; 6: 1104–9.
- 38, . Phamacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers. Curr. Opin. Pharmacol. 2005; 5: 550–5.
- 39, , , , , . Arginine-rich peptide conjugation to morpholino oligomers: Effects on antisense activity and specificity. Bioconjug. Chem. 2005; 16: 959–66.
- 40, , , , . A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 2003; 38: 503–8.
- 41, , , , . Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I safety study in humans. Clin. Cancer Res. 2003; 9: 2510–19.
- 42, . Innovations in oligonucleotide drug delivery. J. Pharm. Sci. 2003; 92: 1559–73.
- 43, , . ‘Smart’ delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv. Drug Deliv. Rev. 2004; 56: 931–46.
- 44, , et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: In vitro and in vivo studies. J. Drug Target. 2004; 12: 393–404.
- 45, . Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res. 2000; 28: 4225–31.
- 46, . The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov. Today 2004; 9: 395–402.
- 47, , . Intracellular uptake and inhibition of gene expression by PNAs and PNA-peptide conjugates. Biochemistry 2004; 43: 14 340–7.
- 48, , , European Colitis Study Group. A randomized, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 2004; 53: 1646–51.
- 49, , et al. Targeted tumor therapy with the TGF-β2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2006; 17: 129–39.
- 50, , , . Toxicity of antisense oligonucleotides. In: CrookeST (ed.). Antisense Drug Technology. Marcel Dekker, New York. 2001; Ch. 9.
- 51, , . Toxicology of antisense therapeutics. Toxicol. Appl. Pharmacol. 2004; 201: 66–83.
- 52, , et al. Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides 2004; 14: 23–31.
- 53, . Recent advances in the development of immunostimulatory oligonucleotides. Curr. Opin. Drug Discov. Dev. 2003; 6: 204–17.
- 54, , et al. Phase II study of G3139, a bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J. Clin. Oncol. 2005; 23: 4089–99.
- 55, , , , , . Phase I to II multicenter study of oblimersen sodium, a bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocyte leukemia. J. Clin. Oncol. 2005; 23: 7697–702.
- 56, , et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res. 2003; 63: 2802–11.
- 57, , et al. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. J. Oncol. 2005; 16: 958–65.
- 58, , et al. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: A phase I study. Clin. Cancer Res. 2004; 10: 72 441–51.
- 59, , et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl Cancer Inst. 2005; 97: 1287–96.
- 60, , , , . Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to trastuzumab. J. Cell. Physiol. 2005; 204: 463–9.
- 61, , , , , . In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res. 2005; 11: 3930–8.